Serious setback for Genmab in DuoBody collaboration

Genmab has suffered a significant setback for one of the early clinical assets being developed in a collaboration with Janssen after a phase I study has been put on clinical hold.

Photo: PR Genmab

“All three have enormous potential, but what is important for me, is that they validate the platform. We now have five commercial agreements against the background of the platform and more than 75 percent of the internal pipeline is based on the technology, so it is profoundly important for Genmab’s future.”

Those were the optimistic and, as per usual, slightly bombastic words from Genmab’s CEO, Jan van de Winkel, back in May when he told MedWatch about the biotech’s DuoBody platform and the partnerships it has struck for it.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles